Keros Therapeutics (KROS) EPS (Weighted Average and Diluted): 2020-2025
Historic EPS (Weighted Average and Diluted) for Keros Therapeutics (KROS) over the last 6 years, with Sep 2025 value amounting to -$0.18.
- Keros Therapeutics' EPS (Weighted Average and Diluted) rose 87.23% to -$0.18 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.56, marking a year-over-year increase of 129.94%. This contributed to the annual value of -$5 for FY2024, which is 3.85% up from last year.
- According to the latest figures from Q3 2025, Keros Therapeutics' EPS (Weighted Average and Diluted) is -$0.18, which was up 76.32% from -$0.76 recorded in Q2 2025.
- Keros Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at $3.62 during Q1 2025, with a 5-year trough of -$1.41 in Q3 2024.
- Its 3-year average for EPS (Weighted Average and Diluted) is -$0.68, with a median of -$1.25 in 2024.
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first tumbled by 266.67% in 2022, then surged by 399.17% in 2025.
- Keros Therapeutics' EPS (Weighted Average and Diluted) (Quarterly) stood at -$0.30 in 2021, then crashed by 266.67% to -$1.10 in 2022, then fell by 21.82% to -$1.34 in 2023, then climbed by 16.42% to -$1.12 in 2024, then surged by 87.23% to -$0.18 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.18 in Q3 2025, compared to -$0.76 in Q2 2025 and $3.62 in Q1 2025.